{"schema_version":"secwatch.filing_event.v1","accession":"0001790340-26-000055","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2026-05-15T11:43:39+00:00","discovered_at":"2026-05-15T11:45:00.340803+00:00","generated_at":"2026-05-15T11:45:20.143491+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Immuneering Q1 net loss $13.5M; cash $198.6M; Phase 3 pancreatic trial recruiting; ASCO data June 1","bullets":["Q1 2026 net loss $13.5M ($0.21 per share) vs $15.0M ($0.42 per share) in Q1 2025.","Cash, equivalents and marketable securities $198.6M (Dec 31, 2025: $217.0M); runway into 2029.","R&D expenses $10.6M (down from $11.5M YoY); G&A expenses $4.7M (up from $4.0M).","Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line pancreatic cancer now recruiting; first patient dosing mid-2026.","Updated survival data from Phase 2a cohort (55 patients) to be presented in oral session at ASCO June 1, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001790340-26-000055","json":"https://secwatch.observer/filing/0001790340-26-000055.json","markdown":"https://secwatch.observer/filing/0001790340-26-000055.md","text":"https://secwatch.observer/filing/0001790340-26-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000179034026000055/0001790340-26-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000179034026000055/imrx-20260515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:45:20.143491+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b431eba6549a84aa81129301cd8cac2d5c257813","claim":"Immuneering Corp reported the first quarter ended March 31, 2026 results: net income $13.5 million, or $0.21 per share, EPS $0.21 per share.","evidence_excerpt":"Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today reported financial results for the first quarter ended March 31, 2026, and provided business updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1790340/000179034026000055/0001790340-26-000055-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Net income","value":"$13.5 million, or $0.21 per share"},{"label":"EPS","value":"$0.21 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}